Clinical trial
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
NCT00002168 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00002168 |
|---|---|
| Title | A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients |
| Official title | An Open Label, Randomized, Comparative Study of Zerit (d4T) + Videx (ddI) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700/mm3 and HIV RNA Baseline Copy Number of >= 10,000 Copies/ml |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine |
| Enrollment | 200 |
| First posted | Aug 31, 2001 |
| Last update posted | Oct 2, 2007 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: